Arbeitsgruppe CUP-Syndrom - geschlossene Studien
CUP palliative Therapie - 2nd-line

AIO-assoziierte Studie   www.clinicaltrials.gov zur Studie

AIO-CUP-0119/ass: A phase II, open-label, non-randomized, multi-center study evaluating the efficacy and safety of nivolumab plus ipilimumab in patients with cancer of unknown primary site who are relapsed after or refractory to platinum-based chemotherapy (CheCUP)

---Studie nicht mehr aktiv ---
 

AIO-assoziierte Studie   ClinicalTrials.gov zur Studie

Open labeled, randomized multi-center phase II study evaluating the efficacy and safety of Paclitaxel/ Carboplatin with and without Cetuximab as first-line treatment of adeno- and undifferentiated CUP (PACET-CUP)
  ---Rekrutierung beendet/ bzw. im Follow up---